By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Washington and Pharmigene today announce the resolution of a patent dispute and the subsequent licensing of technology to Pharmigene for determining proper dosing for the anti-coagulant drug warfarin.

The agreement settles a patent interference "concerning previously competing applications that describe methods to determine proper dosing of … warfarin," the two firms said in a joint statement. No additional details were provided.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.